Swiss peptide and oligonucleotide CDMO with GMP plants in Europe and the US.
- Model
- CDMO
- Manufacturer?
- Yes
5 companies are listed as peptide API manufacturers in Switzerland. 3 hold active US Drug Master Files for peptide APIs, most often for Calcitonin, Leuprolide, Liraglutide. 4 have a regulator record of GMP manufacturing. 4 score High (90 or more).
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Swiss peptide and oligonucleotide CDMO with GMP plants in Europe and the US.
Peptide, HPAPI and bioconjugate manufacturing within Lonza's small-molecule business.
Peptide-focused CDMO running GMP manufacturing sites on three continents.
Privately owned Swiss CDMO near Zurich, in business since 1963, that makes peptide APIs, peptide fragments and amino acid derivatives by solid- and solution-phase synthesis.
Swiss Debiopharm plant in Martigny making triptorelin sustained-release products; US DMF for triptorelin pamoate microgranules.
5 companies. Each listing shows location, business model, documentation and a score from 0 to 100.
By score: Bachem Holding AG (95), Lonza (Peptides) (95), PolyPeptide Group (95), Senn Chemicals (95), Debiopharm Research & Manufacturing SA (75). Scores measure checkable evidence, not product quality, and paid placement does not change them.
Bachem Holding AG, PolyPeptide Group and Debiopharm Research & Manufacturing SA hold active Type II DMFs for peptide APIs in FDA's DMF list. A DMF is a confidential file submitted to FDA; FDA does not approve DMFs, but drug applications can reference them.
Confirm the legal entity, ask for lot-specific certificates of analysis that the testing lab can verify, check FDA warning letters and import alerts, and for GMP material ask for regulator inspection records rather than marketing claims.